Heading: |
Cancer: Medical Treatments |
Question ID: |
1796317 |
UIN: |
47458 |
House: |
Commons |
Date tabled: |
2025-04-23 |
Asking Member ID: |
5197 |
Asking Member display name: |
Dr Neil Shastri-Hurst
|
Asking Member handle: |
drnshastrihurst
|
Asking Member Twitter reference: |
@drnshastrihurst
|
Member interest: |
false |
Question text: |
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the (a) development and (b) approval of (i) second- and third-line tyrosine kinase inhibitors and (ii) other targeted therapy options for patients wit |
Is named day: |
false |
Date of holding answer: |
|
Date answered: |
2025-04-30 |
Date answer corrected: |
|
Is holding answer: |
false |
Is correcting answer: |
false |
Answering Member ID: |
4444 |
Answering Member display name: |
Karin Smyth
|
Answering Member handle: |
karinsmyth
|
Answering Member Twitter reference: |
@karinsmyth
|
Correcting Member ID: |
|
Correcting Member display name: |
|
Correcting Member handle: |
|
Correcting Member Twitter reference: |
|
Answer text: |
The National Institute for Health and Care Excellence (NICE) is the independent body that develops recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of clinical a... |
Original answer text: |
|
Comparable answer text: |
|
Answering body ID: |
17 |
Answering body name: |
Department of Health and Social Care |
Tweeted: |
true |